NIH Funding · FY2024
Total Funding
$2M
Fiscal year 2024
Grants Awarded
3
Active NIH grants
National Rank
#5,287
Among 57,894 PIs
First NIH Award
2024
Year of first funding
Funding & rank history
NIH funding totals and national rank by fiscal year.
Single fiscal year on record (FY2024): $2M across 3 grants · National rank #5287.
Top grants by award amount
Wassana Yantasee's NIH grant portfolio, ranked by award amount.
- 5R44CA265751-03R44Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932.8Kaward amount
- 4R44CA285233-02R44PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$914.2Kaward amount
- 1SB1CA287735-01A1SB1Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$160.7Kaward amount
Affiliation
Institutions that have administered grants for Wassana Yantasee.
Affiliated with Pdx Pharmaceuticals, Inc. (OR).
Career milestones
Key NIH funding milestones over time.
- 2024First NIH AwardPdx Pharmaceuticals, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #5287
Related investigators
Other NIH-funded PIs frequently associated with Wassana Yantasee.
Explore further
Find collaborators for Wassana Yantasee
Search NIH-funded principal investigators by topic, department, or activity.
Open Find Collaborators →Check S10 eligibility at Pdx Pharmaceuticals, Inc.
Review past S10 Shared Instrumentation Grant awards and equipment categories.
Open S10 Eligibility Finder →Benchmark grant budgets
Compare median NIH grant budgets across departments, mechanisms, and years.
Open Grant Budget Benchmark →